AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

Psychedelic stocks rise after report on AbbVie's (ABBV) deal talks to acquire Gilgamesh Pharmaceuticals in a transaction ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

AbbVie raised its 2025 earnings forecast after a strong Q2, despite $3 billion in deal costs tied to acquisitions of Capstan ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...

AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net ...

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...